(Q38128809)

29 August 2017

title

Tofacitinib for treatment of rheumatoid arthritis (English)

1 reference

29 August 2017

1 reference

2

1 reference

29 August 2017

Chadi Rakieh

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

14 August 2013

1 reference

29 August 2017

number of pages

14

1 reference

based on heuristic

inferred from page(s)

published in

Advances in Therapy

1 reference

29 August 2017

volume

30

1 reference

29 August 2017

issue

8

1 reference

29 August 2017

page(s)

713-726

1 reference

Early rheumatoid arthritis: strategies for prevention and management

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Biologic therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Janus kinases in immune cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Stats: transcriptional control and biological impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-013-0047-Y

10.1007/S12325-013-0047-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1037909207

0 references

1 reference